Hubei Biocause Pharmaceutical Co., Ltd.

Symbol: 000627.SZ

SHZ

2.3

CNY

Market price today

  • -19.6629

    P/E Ratio

  • 0.1626

    PEG Ratio

  • 11.27B

    MRK Cap

  • 0.05%

    DIV Yield

Hubei Biocause Pharmaceutical Co., Ltd. (000627-SZ) Financial Statements

On the chart you can see the default numbers in dynamics for Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Hubei Biocause Pharmaceutical Co., Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993

balance-sheet.row.cash-and-short-term-investments

02995228391.826157.8
30248.8
15203.5
18317.5
15336.9
10953.2
61.6
58.9
124.3
152.8
74.1
72.9
95.1
306.7
111.3
73.5
26.9
16.8
55.5
73.7
247
104.9
74.6
96
104.9
113.5
13.9
13.9
13.6

balance-sheet.row.short-term-investments

01798.42082.52907.5
3391.6
2211.8
62842.7
4164.8
50767.4
418.6
0
0
0
0
0
0
16.1
3.2
1.3
0
0
0
1.4
0
0
0
0
12
0
13.5
13.5
13.5

balance-sheet.row.net-receivables

00-28453.617772.1
15069.6
10639.8
45548.8
9204.3
7697.9
83.7
140.8
188.6
339.1
391
277
295.6
231
198.2
318.7
428
407.2
455.9
280.7
296.1
28.7
8.7
8
4.1
5.6
3.4
0.2
26

balance-sheet.row.inventory

04131.91050410224.5
10716.2
3671.6
3820.5
569.4
438.5
136.1
140.4
133.9
134.4
150.2
194.2
273.9
259.2
200.4
156.1
135
128.6
125.8
129.8
90.7
70.6
75.6
66.7
16.1
30
18.4
5.3
1.4

balance-sheet.row.other-current-assets

0045535.3-3796
-4291.5
-3729.8
-17868.2
2283.9
645.2
57.7
53.8
-8.1
-98.7
-45.5
-33.6
-29.1
-26.9
0.1
-93.8
-146.6
-130.9
-169.3
0
-105.7
171.7
92.1
73.9
23.9
18.1
23.2
19
-12.8

balance-sheet.row.total-current-assets

050665.955977.650358.4
51743.1
25785
49818.6
27394.5
19734.9
339.2
394
438.7
527.6
569.9
510.5
635.5
770
510
454.5
443.3
421.7
467.9
484.2
528.1
375.9
251.1
244.7
149
167.2
58.9
38.3
28.2

balance-sheet.row.property-plant-equipment-net

01290.6844.1830.3
580.4
567.2
770.9
698.9
587.4
334.7
454.2
619.2
601.7
448.9
527
798.5
612.4
374.3
354.7
336.6
343.3
338.4
322.2
262.9
355.1
376.4
274.9
159.7
111.5
63
32.9
26.5

balance-sheet.row.goodwill

06192.56192.26192.2
6192.2
6186.3
6186.3
6186.3
6186.3
0
0
0
0
0
1.8
1.8
1.8
1.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0283.2299.3269.7
190
109.4
213.4
519.9
549.1
490.4
503.9
363.5
374.7
382.8
410.6
363.6
316.5
261.9
257.6
179.6
186.8
189.1
184.4
123.5
105
109.3
16.4
16.8
16.3
10.8
3.8
3.9

balance-sheet.row.goodwill-and-intangible-assets

06475.76491.66461.9
6382.2
6295.7
6399.7
6706.2
6735.4
490.4
503.9
363.5
374.7
382.8
412.3
365.4
318.3
263.7
257.6
179.6
186.8
189.1
184.4
123.5
105
109.3
16.4
16.8
16.3
10.8
3.8
3.9

balance-sheet.row.long-term-investments

0133897.1129743.213020.4
12217.8
12396.1
12983.8
15056.2
8280.1
742
716.8
689.8
543.4
463.3
517.5
330.1
260.4
172.5
100.1
127
127.3
94
100.6
74.4
43.9
22.5
139.1
12
0
13.5
13.5
13.5

balance-sheet.row.tax-assets

026542280.31010.3
976.2
944.2
1189.4
39.5
69.8
69.3
30.5
45.7
17.3
18.7
8.9
9.1
7.6
4.7
-2.7
-127
-127.3
-94
-2.7
0
1.8
1.9
2.3
-12
0
-13.5
-13.5
-13.5

balance-sheet.row.other-non-current-assets

0106952.593262192222.6
167502.9
159285.8
107091.6
90521.3
82469.2
433.6
9.1
0
0
0
0
17.2
10.9
-0.7
3.2
128.4
129.5
95.6
1.7
0.2
4.6
9.4
5
44.3
35.9
1.7
3.1
1.4

balance-sheet.row.total-non-current-assets

0251270232621.1213545.5
187659.6
179488.9
128435.4
113022.2
98141.8
2070.1
1714.5
1718.3
1537.1
1313.7
1465.8
1520.3
1209.6
814.6
712.9
644.6
659.6
623.1
606.2
461
510.4
519.5
437.8
220.8
163.8
75.5
39.8
31.8

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

0301935.9288598.7263904
239402.6
205273.9
178254
140416.7
117876.7
2409.2
2108.5
2157
2064.7
1883.6
1976.3
2155.7
1979.5
1324.5
1167.4
1087.9
1081.3
1091
1090.4
989.1
886.3
770.7
682.5
369.8
331
134.4
78.2
60.1

balance-sheet.row.account-payables

0949206.993.5
35
156.5
83.5
106.1
82.8
74.4
112.8
208.7
84.8
62.6
34.8
37.5
45
67.9
119.6
45.7
51
25.7
26.8
18.6
51.6
29.5
40.1
19
12.5
7.5
3.1
0

balance-sheet.row.short-term-debt

018248.121189.69425.8
4583.8
6179.8
4640
7732.3
1414
303.5
428.9
484.6
327.8
253.2
142.8
274.8
192.7
279.4
231.9
252.4
251.4
284.4
249.4
134.5
154.4
96.4
54.9
7.7
14.9
8.1
3.3
6

balance-sheet.row.tax-payables

078.585.1142.5
65.4
223.8
338.4
19.2
53.3
2.1
3.7
-43.3
-48.5
-9.7
0.6
6.9
2.8
29.3
11.2
3.6
2.4
6.6
9.7
32
26.4
15.4
6.2
6.6
15.1
8.8
10.5
2.2

balance-sheet.row.long-term-debt-total

07170.86877.96203.6
2760.3
-69.4
110.5
40.5
360
42
0
0
23
123
123
225
160
30
30
0
0
0
0
0
9
14
14
58.4
56.8
24.4
2.7
5.8

Deferred Revenue Non Current

0179576.7241.8154781.7
147076.1
69.4
10.9
15.3
16
17.6
19.4
0
0
0
0
0
-160
-30
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

0463347.4258.5
52
69.4
21424.5
8957.1
2072
8.3
8.8
14.5
12.6
5.9
13.1
20.5
11.8
17.6
21.7
23.7
22.7
19.3
16.8
8.2
12.8
5.3
4.9
0.8
6.4
1.5
0.8
6.9

balance-sheet.row.total-non-current-liabilities

0243840.1229010213369.4
196798.4
162486.6
125753.1
103441.9
93669.4
198.5
41.3
15.8
34.8
134.5
134.5
225
160.2
30
30
0
0
0
0
0
9
16.2
15.2
58.4
56.8
24.4
2.7
5.8

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

071.689.6111.2
69.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

0268302.2253995.8226429.3
204814.7
170920.5
152239.5
113711.8
97479.2
625.5
618.8
720.7
527.4
469.5
374.2
581.3
466.8
458.5
443.7
356.7
357.4
372.2
322.4
226.1
291.8
199
189.5
176.6
130.9
82
34.3
18.8

balance-sheet.row.preferred-stock

001085.90
763.7
595.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

04940.64940.64940.6
4940.6
4940.6
4940.6
4940.6
4259.2
1353.6
1353.6
1353.6
1353.6
1353.6
1353.6
676.8
676.8
594.8
594.8
594.8
594.8
594.8
594.8
517.2
278.9
232.4
129.1
103.2
103.2
40.5
40.5
40.5

balance-sheet.row.retained-earnings

053106508.56327.4
5909.4
5829
4247.5
3142.4
1922.7
184.6
-37
-171.9
-70.8
-82.7
19
104.6
58.6
106.1
13.1
-31.5
-37.4
-41.7
6.4
27.8
73.4
59.9
36.2
12
32.9
3.4
0
0.8

balance-sheet.row.accumulated-other-comprehensive-income-loss

00-1085.9236.6
-763.7
-595.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

010339.49962.811048.6
10284.9
10453.5
9804
11254
7619.9
201.5
132.4
214.1
214.7
105.3
172.4
736.8
726.2
113.6
99.1
94.7
93.5
92.8
92.8
143.6
175.4
215.1
312.4
77.9
64
8.5
3.3
0

balance-sheet.row.total-stockholders-equity

020590.12141222553.3
21134.9
21223.1
18992.1
19337
13801.8
1739.7
1449
1395.8
1497.5
1376.2
1545
1518.2
1461.6
814.5
707
658
650.9
645.9
694
688.7
527.7
507.4
477.7
193.2
200.1
52.4
43.9
41.3

balance-sheet.row.total-liabilities-and-stockholders-equity

0301935.9288598.7263904
239402.6
205273.9
178254
140416.7
117876.7
2409.2
2108.5
2157
2064.7
1883.6
1976.3
2155.7
1979.5
1324.5
1167.4
1087.9
1081.3
1091
1090.4
989.1
886.3
770.7
682.5
369.8
331
134.4
78.2
60.1

balance-sheet.row.minority-interest

013043.71319114921.3
13453
13130.4
7022.5
7367.8
6595.7
44
40.7
40.4
39.9
37.9
57
56.3
51.2
51.6
16.7
73.2
73
72.9
74.1
74.3
66.8
64.2
15.3
0
0
0
0
0

balance-sheet.row.total-equity

033633.834602.937474.7
34587.9
34353.5
26014.5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0135695.6131825.7116261.7
119224.9
120538.2
75826.6
61072.9
59047.4
1160.6
716.8
689.8
543.4
463.3
517.5
330.1
244.3
169.3
98.7
127
127.3
94
99.2
74.4
43.9
22.5
139.1
24
0
27
27
27

balance-sheet.row.total-debt

025418.928067.59425.8
4583.8
6179.8
4640
7732.3
1414
303.5
428.9
484.6
327.8
253.2
142.8
274.8
192.7
279.4
231.9
252.4
251.4
284.4
249.4
134.5
154.4
96.4
54.9
7.7
14.9
8.1
3.3
6

balance-sheet.row.net-debt

0-2734.71758.2-13824.5
-22273.3
-6811.9
-13677.5
-3439.9
-9539.2
241.9
370
360.3
175
179.1
69.9
179.7
-97.9
171.4
159.7
225.5
234.6
228.9
177.1
-112.5
49.6
21.7
-41.1
-85.2
-98.7
7.7
2.9
5.9

Cash Flow Statement

The financial landscape of Hubei Biocause Pharmaceutical Co., Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998

cash-flows.row.net-income

0510.6880.21117.9
2918.6
2377.3
2678.3
3108.8
250.5
84.1
-100.4
13.8
-107.2
29.1
55.3
17.1
101.6
53.1
8.1
4.9
-49
7.8
46.7
40.3
35.4
30.5

cash-flows.row.depreciation-and-amortization

0147.3133.963.7
79.2
1123.9
122.9
139.3
64.8
73.5
68.8
52.4
62.9
66.5
52.3
40.5
42
35.6
37.6
35.9
34.2
37.3
28.9
28.6
25.1
13.1

cash-flows.row.deferred-income-tax

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

016073.111933.530709.3
35361
-26789.8
5245.9
-6232.5
23.9
-78.9
116.7
78
51.7
149.3
-122.8
-96.1
27.3
51.8
-13.7
15
-22.3
-131.2
-41.5
-83.5
-23.6
-52.1

cash-flows.row.account-receivables

01642.4-609.1-279.5
1548.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-279.6471.1-188.3
177.6
120.5
-130.9
-302.4
1.7
-6.5
0.5
15.8
12.3
79.7
-14.7
-58.7
-44.4
-21
-6.4
-1.8
4
-37.2
-20.1
4.9
8.9
-29

cash-flows.row.account-payables

0-1642.4609.1279.5
-1548.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

016352.611462.530897.6
35183.5
-26910.3
5376.7
-5930.1
22.2
-72.4
116.2
62.2
39.5
69.6
-108.1
-37.3
71.6
72.9
-7.3
16.8
-26.3
-94
-21.4
-88.4
-32.5
-23.1

cash-flows.row.other-non-cash-items

0-9206.7-8775.1-10469.8
-9759.2
38269.9
-7615.5
642
-385.9
-200
45.4
-50.4
59.5
-20.2
-5.3
24.9
-52.3
-12.4
16.7
0.3
11.2
16.5
3.2
10
10
3.4

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-135.1-287.1-308.4
-717.1
-274.7
-778.9
-3678.3
-40.8
-185.5
-143.8
-128.5
-149.4
-93.1
-261.7
-361.7
-64.8
-130.1
-24.5
-25.5
-21.5
-146.1
-31.5
-6.3
-99.2
-10.8

cash-flows.row.acquisitions-net

0171.8-3440.5
258.8
334.3
1.4
3.5
3.2
103.1
162.9
131
44.3
0
263.4
361.8
65.9
130.1
0
28.3
21.8
146.9
0.2
10.7
0
10.8

cash-flows.row.purchases-of-investments

0-97626.8-109755-71494.6
-123082.8
-77372.7
-139091.6
-115403.5
-6.2
-230
-146.7
-60
-40
-120.1
-40
-189
-60
-55.6
-0.8
-39
-165.8
-184.7
-24.8
-20.2
0
-31.5

cash-flows.row.sales-maturities-of-investments

084126.194717.767783.5
88942.6
68035
129051.5
104526.6
182.1
464.4
89
130
170
0
17.8
92.7
43.2
26.7
0
15.6
175.7
129.6
1.1
12.2
29.9
12

cash-flows.row.other-investing-activites

0-1996.2-62.2-222.2
-445.9
102.8
-47.8
17138.3
7.1
5.3
-143.8
-128.5
-149.4
207.6
-261.7
-361.7
-64.8
-130.1
0
-25.5
-21.5
-146.1
62
-6.3
0.5
-10.8

cash-flows.row.net-cash-used-for-investing-activites

0-15615-15384.8-7682.2
-35044.3
-9175.3
-10865.4
2586.6
145.4
157.2
-182.4
-56
-124.4
-5.6
-282.2
-458
-80.4
-159
-25.3
-46.2
-11.3
-200.6
7
-9.9
-68.8
-30.3

cash-flows.row.debt-repayment

0-11763.8-7701.9-854.1
-102.8
-288
-790
-447.5
-464.9
-573.5
-463.3
-294.8
-223.3
-594.8
-279.7
-413.2
-231.9
-255.8
-240.6
-235.4
-329.9
-345.9
-178.9
-59.8
-67.9
-17.2

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-699.4-381.3-634
-242.1
-311.6
-148
-117.1
-24.5
-30.6
-30.4
-28.7
-21.6
-37.3
-20
-52.4
-17.8
-12.3
-14.3
-15.5
-15
-16.1
-22.7
-15.1
-6.2
-58.7

cash-flows.row.other-financing-activites

02354115703.91660.6
1470.2
1940.4
11597.1
11190.3
407
515.3
484.6
364.4
303.7
390.8
406.8
1119.6
247.4
344.2
241.6
202.4
364.9
457.5
299.4
119.6
74.8
114.5

cash-flows.row.net-cash-used-provided-by-financing-activities

011077.87620.6172.6
1125.3
1340.8
10659.2
10625.7
-82.4
-88.8
-9.1
40.9
58.8
-241.3
107.2
654.1
-2.3
76.2
-13.3
-48.6
20
95.5
97.8
44.7
0.6
38.6

cash-flows.row.effect-of-forex-changes-on-cash

072-15.2-33.9
-1.4
1.6
-2.1
3.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0

cash-flows.row.net-change-in-cash

03059-3606.913877.6
-5320.8
7148.4
223.2
10873.7
16.2
-52.8
-61.1
78.7
1.3
-22.2
-195.5
182.6
35.8
45.3
10
-38.7
-16.8
-174.7
142.2
30.2
-21.4
3.1

cash-flows.row.cash-at-end-of-period

026309.323250.326857.1
12979.5
18300.4
11152
10928.8
55.1
38.9
91.8
152.8
74.1
72.9
95.1
290.6
108
72.2
26.9
16.8
55.5
72.3
247
104.9
74.6
96

cash-flows.row.cash-at-beginning-of-period

023250.326857.112979.5
18300.4
11152
10928.8
55.1
38.9
91.8
152.8
74.1
72.9
95.1
290.6
108
72.2
26.9
16.8
55.5
72.3
247
104.9
74.6
96
92.9

cash-flows.row.operating-cash-flow

07524.24172.621421.1
28599.6
14981.3
431.6
-2342.3
-46.7
-121.3
130.5
93.8
66.9
224.6
-20.5
-13.5
118.6
128.2
48.7
56.1
-25.9
-69.6
37.3
-4.6
46.9
-5.2

cash-flows.row.capital-expenditure

0-135.1-287.1-308.4
-717.1
-274.7
-778.9
-3678.3
-40.8
-185.5
-143.8
-128.5
-149.4
-93.1
-261.7
-361.7
-64.8
-130.1
-24.5
-25.5
-21.5
-146.1
-31.5
-6.3
-99.2
-10.8

cash-flows.row.free-cash-flow

07389.13885.521112.7
27882.5
14706.7
-347.4
-6020.6
-87.5
-306.8
-13.3
-34.7
-82.4
131.5
-282.2
-375.2
53.8
-1.9
24.1
30.5
-47.4
-215.8
5.8
-10.9
-52.3
-16

Income Statement Row

Hubei Biocause Pharmaceutical Co., Ltd.'s revenue saw a change of NaN% compared with the previous period. The gross profit of 000627.SZ is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

income-statement-row.row.total-revenue

049725.849615.749583.2
43576
50192.1
30950.8
53405.6
16995.5
541.1
806.4
968
779.7
1133.8
1261.2
964.6
909.3
835.8
560.8
518.7
463
422.7
348.6
356
322
255.9
192.3
237.5
143.7
83.3

income-statement-row.row.cost-of-revenue

09829.68458.67311.6
3225.1
8172.6
2866.9
4036.6
1788.5
518
829.8
977.5
753.2
1111.8
1185.8
866.2
835.1
726.1
475.6
451.1
410.6
380.8
268.7
261.2
240.2
193
155.3
176.4
98.2
53.9

income-statement-row.row.gross-profit

039896.241157.142271.6
40350.8
42019.5
28083.9
49368.9
15207
23.1
-23.4
-9.6
26.5
22
75.3
98.4
74.2
109.7
85.1
67.7
52.5
41.8
79.9
94.9
81.8
62.8
37
61.2
45.6
29.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0-48509.69825.59896.8
36146.5
30062.1
-24280.3
-23688.3
-6190.4
3.1
8.3
13.2
1.5
0.3
9.8
6
5
6
10.3
4.7
9.5
1.5
2.6
8.3
7.3
20.6
11.9
5.6
6.6
2

income-statement-row.row.operating-expenses

0-48509.610159.510437.9
36774.7
30668.5
2614.7
26761
6911.4
79.6
70.9
73.6
63.9
80.2
67.9
52.8
59
55.4
45.9
49.3
50.8
83.4
57
45
36.6
36.2
13
10
10.3
6.8

income-statement-row.row.cost-and-expenses

0-51566.718618.117749.5
39999.8
38841.1
5481.6
30797.6
8699.9
597.6
900.7
1051.1
817.1
1192
1253.7
919
894.1
781.4
521.5
500.4
461.3
464.2
325.6
306.1
276.7
229.2
168.3
186.3
108.5
60.7

income-statement-row.row.interest-income

0000
0
0
0
16.1
0
2.3
2.6
1.5
2.2
3.7
1.8
2.7
14.7
4.2
3.9
0.5
3.2
0.2
1.7
5.2
1.5
0
0
0
0
0

income-statement-row.row.interest-expense

0031200.6423.8
170.5
101.3
0
0
0
24.5
30.6
30.4
28.7
21.6
25.8
23.3
32.1
21
16.1
14.3
13.9
15.5
10.7
8.5
8.3
-0.4
-0.6
0.3
1.4
0.3

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-1868-30964.1-32573.9
-2432.1
-8419.3
-18306.3
-4428.3
-1585.5
390.9
203.2
-45.4
52.4
-58.5
23.6
13.6
-7.9
58.1
13.2
-14.4
0.5
-9.5
-9.1
-0.2
-3.1
6.1
12.8
6.6
10.1
6.2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0-48509.69825.59896.8
36146.5
30062.1
-24280.3
-23688.3
-6190.4
3.1
8.3
13.2
1.5
0.3
9.8
6
5
6
10.3
4.7
9.5
1.5
2.6
8.3
7.3
20.6
11.9
5.6
6.6
2

income-statement-row.row.total-operating-expenses

0-1868-30964.1-32573.9
-2432.1
-8419.3
-18306.3
-4428.3
-1585.5
390.9
203.2
-45.4
52.4
-58.5
23.6
13.6
-7.9
58.1
13.2
-14.4
0.5
-9.5
-9.1
-0.2
-3.1
6.1
12.8
6.6
10.1
6.2

income-statement-row.row.interest-expense

0031200.6423.8
170.5
101.3
0
0
0
24.5
30.6
30.4
28.7
21.6
25.8
23.3
32.1
21
16.1
14.3
13.9
15.5
10.7
8.5
8.3
-0.4
-0.6
0.3
1.4
0.3

income-statement-row.row.depreciation-and-amortization

01840.9147.3133.9
63.7
79.2
1123.9
122.9
139.3
64.8
73.5
68.8
52.4
62.9
66.5
52.3
40.5
42
35.6
37.6
35.9
34.2
37.3
28.9
28.6
25.1
13.1
-11.9
-13.4
-8.3

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

01216.331188.832917
3881.5
12052.8
2653.6
2727.4
3424.8
332.2
101.1
-141.1
14.9
-113.7
22.2
53.2
2.3
106.4
53.1
8.2
-1.7
-45.1
15.8
57.5
48.3
41.8
30.7
63.1
48.6
30.8

income-statement-row.row.income-before-tax

0-1868224.8343.1
1449.5
3633.4
2636.4
2724.3
3432.6
334.4
109
-128.6
15
-116.7
31.1
59.2
7.3
112.4
57.9
8.4
5
-47.3
16.2
57.7
48.9
47.6
39.7
63.3
50.3
30.8

income-statement-row.row.income-tax-expense

0-1216.3-285.8-537.1
331.6
714.9
259.1
46
323.7
83.9
24.8
-28.1
1.2
-9.5
2
3.9
-0.1
20.5
4.8
0.3
0.1
1.7
8.3
11
8.5
12.2
9.2
8.5
13.4
8

income-statement-row.row.net-income

0-651.8510.6880.2
1117.9
2918.6
1326.5
1326.2
1778.7
247.3
83.8
-101
11.8
-101.7
28.3
55.8
-23.8
89.7
48.4
7.1
5.1
-48.1
5.3
37.2
34.2
31.3
30.2
54.8
36.9
22.8

Frequently Asked Question

What is Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) total assets?

Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) total assets is 301935930342.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 0.698.

What is company free cash flow?

The free cash flow is -2.454.

What is enterprise net profit margin?

The net profit margin is -0.007.

What is firm total revenue?

The total revenue is 0.006.

What is Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) net profit (net income)?

The net profit (net income) is -651784800.000.

What is firm total debt?

The total debt is 25418877126.000.

What is operating expences number?

The operating expences are -48509569700.000.

What is company cash figure?

Enretprise cash is 0.000.